Wire · opportunities
FDA approves AZ's Etcamah for pre-progression switch in HR+ breast cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 8 September 2026 · Fusion42 review
The US FDA has granted accelerated approval to AstraZeneca's Etcamah (camizestrant) for a pre-progression switch in adult patients with HR-positive, HER2-negative advanced breast cancer who develop ESR1 mutations during first-line AI and CDK4/6 inhibitor therapy, enabled by an FDA-approved companion diagnostic test.
This Wire brief sits within Fusion42's coverage of Biotech, and 12 sources have reported it between 4 Sep 2026 and 8 Sep 2026.
◆ ◆ The Wire takeaway
You must adapt your breast cancer drug development approach to include ctDNA-guided early intervention strategies like Etcamah's. Competitors not integrating pre-progression mutation detection risk losing ground to personalised therapy advances.
◆ Coverage
12 sources · first reported 4 Sep 2026 · latest 8 Sep 2026
◆ Related on Wire
◆ Topics